Legend Biotech (LEGN) Q2 2026 Earnings Call Transcript
Legend Biotech (LEGN) reported Q2 2026 results on an earnings call. Worldwide CARVYKTI net trade sales were $657 million, up 50% YoY. Total revenue was $387.5 million, up 52% YoY, with adjusted net income of $63.1 million ($0.16/share). Cash was $965 million. Q3 gross margin guidance was in the lower 50% range.
How this was made
The 30-second read
Why it matters
Traders will likely focus on the combination of strong CARVYKTI net trade sales growth and the explicit Q3 gross margin guidance to the lower 50% range, which can shift near-term earnings expectations even as cash and operating leverage improve.
Market read
The call provides actionable near-term guidance (Q3 gross margin range) alongside strong commercial momentum (CARVYKTI sales growth) and balance-sheet strength (cash $965 million).
What to watch
The article emphasizes accounting/tax items (pending China APA) and collaboration revenue reporting divergence, which can distort headline profitability versus underlying product economics.
Background
This is Legend Biotech’s Q2 2026 earnings call transcript, covering CARVYKTI commercial performance, profitability, cash position, and early clinical readouts for in vivo CAR-T programs.
Ticker impact
Legend Biotech reported Q2 2026 results and guided Q3 gross margin to the lower 50% range, down from 58% in Q2.
Near-term volatility likely, with upside support from CARVYKTI net trade sales growth and cash build, offset by margin compression guidance.
The article provides multiple hard datapoints (revenue, adjusted net income, cash, and a specific Q3 margin range) that can drive revisions to near-term estimates and valuation multiples, while longer-term in vivo CAR-T and first-line multiple myeloma targets are more speculative.
Market effects
CAR-T commercial execution remains a key read-across for cell therapy peers, with margin trajectory and outpatient mix highlighted as drivers.
International revenue growth and FX sensitivity are explicitly flagged as a source of reporting divergence with collaboration partner.
China tax APA impact and settlement intent on the J&J loan can affect biotech cash flow optics and effective tax rate expectations globally.
Counterpoint
The lower-50% Q3 gross margin guide may be temporary, and management’s stated rebound to mid-50% in Q4 plus operating leverage could limit downside.
Key entities
- companyLegend Biotech Corporation
Subject of the earnings call, reporting Q2 2026 results and providing Q3 margin guidance plus clinical and pipeline updates.
- productCARVYKTI (cilta-cel)
Lead CAR-T therapy whose worldwide net trade sales grew 50% YoY to $657 million in Q2 2026.
- clinical_programLB2501
In vivo CAR-T program with Phase I data cited: 100% ORR and 83.3% complete response at the second dose level in NHL.
- clinical_programLB2102
In vivo CAR-T program with Phase I data cited: 28.6% ORR and 78.6% disease control rate in heavily pretreated small cell lung cancer.
